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Abstract
Reduced pulmonary function and elevated serum cholesterol levels are recognized risk fac-
tors for cardiovascular disease. Currently, there is some controversy concerning relation-
ships between cholesterol, LDL-cholesterol, HDL-cholesterol, serum triglycerides and lung
function. However, most previous studies compared patients suffering from chronic obstruc-
tive pulmonary disease (COPD) with healthy controls, and only a small number examined
this relationship in population-based cohorts. Moreover, lipoprotein a [Lp(a)], another lipid
parameter independently associated with cardiovascular diseases, appears not to have
been addressed at all in studies of lung function at the population level. Here, we deter-
mined relationships between lung function and several lipid parameters including Lp(a) in
606 older community-dwelling participants (55.1% women, 68±4 years old) from the Berlin
Aging Study II (BASE-II). We found a significantly lower forced expiration volume in 1 sec-
ond (FEV1) in men with low Lp(a) concentrations (t-test). This finding was further substanti-
ated by linear regression models adjusting for known covariates, showing that these
associations are statistically significant in both men and women. According to the highest
adjusted model, men and women with Lp(a) levels below the 20th percentile had 217.3ml
and 124.2ml less FEV1 and 239.0ml and 135.2ml less FVC, respectively, compared to par-
ticipants with higher Lp(a) levels. The adjusted models also suggest that the known strong
correlation between pro-inflammatory parameters and lung function has only a marginal
impact on the Lp(a)-pulmonary function association. Our results do not support the hypothe-
sis that higher Lp(a) levels are responsible for the increased CVD risk in people with
reduced lung function, at least not in the group of community-dwelling older people studied
here.
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Introduction
Reduced lung function has been associated with cardiovascular disease (CVD) and risk of mor-
tality; parameters of lung function have been identified as predictors of cardiovascular events,
independently of age, gender or smoking habits [1–10]. In fact, CVDs are the most common
cause of death in pulmonary diseases such as chronic obstructive pulmonary disease (COPD)
[11]. The prevalence of CVDs in subjects suffering from lung function decline further increases
in the context of metabolic syndrome, abdominal obesity and diabetes mellitus (T2D)
[6,12,13].
Plasma lipoproteins have long been recognized as important factors modulating the risk of
CVD [14–16]. Of these, total cholesterol and its subfractions high-density lipoprotein (HDL-
cholesterol) and low-density lipoprotein (LDL-cholesterol), have been studied intensively in
relation to their association with pulmonary function, mostly in the context of COPD [17–19].
The results of these studies on non-clinical cohorts, however, are somewhat contradictory. For
example, Gunell and colleagues analyzed data from 2,338 study participants with a mean age of
about 45 years and showed an inverse association between the forced expiratory volume in 1
second (FEV1) and total cholesterol in men and women [20].
In another study investigating 14,135 subjects in the NHANES III survey (mean age 44 ± 20
years) HDL-cholesterol and its apolipoprotein, ApoAI, were positively associated with FEV1
whereas LDL-cholesterol and its primary apolipoprotein, ApoB, were negatively associated
with FEV1. The authors discuss these results in the context of adverse LDL-cholesterol effects
exerted by its contribution to the endogenous oxidative burden and thereby to the pathophysi-
ology of lung disease, in contrast to the positive effects of HDL-cholesterol with respect to
immunological function and its role in preventing lung tissue damage [17]. Indeed, systemic
inflammation might be the link between HDL-cholesterol, LDL-cholesterol and lung function,
since the levels of the general inflammation markers C-reactive protein (CRP), interleukin-6
(IL-6) and other markers of inflammation were shown to be increased in lung disease [21].
Cholesterol is also known to be involved in inflammatory processes associated with atherogenic
effects [22]. The interaction between CVD and two of its risk factors, reduced lung function
and LDL-cholesterol, has been linked to systemic inflammation [22–24]. Current working
hypotheses include the assumption that a systemic inflammatory process, as found in lung dis-
ease further promotes CVD [25].
Lipoprotein (a) [Lp(a)] is another lipoprotein associated independently with CVD and coro-
nary heart disease (CHD) as well as with cardiovascular mortality [26–28]. In contrast to other
lipoproteins, the serum level of Lp(a) is predominantly genetically determined with an estimated
genetic contribution of more than 90% [29]. Lp(a) consists essentially of LDL-like particles cova-
lently linked to the high molecular weight glycoprotein apolipoprotein (a) [apo (a)] via a disul-
phide bond [30,31]. Lp(a) is synthesized in the liver and it is suggested that the kidney plays a
role in Lp(a) catabolism [32]. The physiological function of Lp(a) remains elusive.
To the best of our knowledge the relationship between Lp(a) and pulmonary function has
not been investigated in the general healthy population. We therefore analyzed data from the
sub-cohort of older community-dwelling Berlin Aging Study II (BASE-II) participants with
respect to the association of lung function and lipid parameters, with a focus on Lp(a).
Material and Methods
Study participants
We analysed baseline cross-sectional data from the Berlin Aging Study II (BASE-II). This
study, described earlier in detail [33], was launched to investigate mechanisms of disease
Lipoprotein (a) in Pulmonary Function
PLOS ONE | DOI:10.1371/journal.pone.0139040 September 30, 2015 2 / 11
Competing Interests: The authors have declared
that no competing interests exist.
development and factors associated with "healthy" and "unhealthy" aging in residents of the
greater Berlin, Germany, metropolitan area by using (bio)medical, psychological, socio-eco-
nomic and genetic data in a multidisciplinary approach. The BASE-II study population con-
sists of community-dwelling elderly people (60–84 years old) and a control group of younger
participants (20–36 years old). For the present study we excluded subjects younger than 60
years and participants with prevalent bronchial asthma, with a spirometric measurement not
reaching the good grade quality criteria (see below) or missing Lp(a) laboratory data. This
resulted in the group of 606 elderly subjects studied here. All participants gave written
informed consent and the Ethics Committee of the Charité—Universitätsmedizin Berlin
approved the study (approval number EA2/029/09).
Lung function
A pre-bronchodilatator lung function test was performed using the EasyOne™ Spirometer (ndd
Medizintechnik AG, Zurich, Switzerland). Spirometry was carried out according to the ATS/
ERS recommendations [34]. Only spirometric measurements with a sufficient level of quality
were included (minimum of two acceptable tests; difference of the two best FEV1- (forced expi-
ratory volume in 1 second) and FVC- (forced vital capacity)-values had to be less than or equal
to 200 ml). We used the FEV1/FVC ratio as an indicator of pulmonary obstruction. Predicted
values of FEV1 and FVC were calculated using ECCS/ERS (European Community for Coal
and Steel/European Respiratory Society) reference values [35].
Laboratory measurements
Blood was drawn from all participants after>8 hours fasting and kept at 4–8°C until analysis
on the same day. Lp(a) analyses were done on plasma using immunological turbidity tests. The
other lipid parameters were measured in serum using enzymatic colorimetric tests. Thyroid-
stimulating hormone (TSH) was measured using an electro-chemiluminescence immunoassay
(ECLIA). TSH-levels< 0.27 mU/l and> 4.6 mU/l were determined as hyper-/hypothyreotic.
Creatinine was measured by a kinetic colour test and glomerular filtration rate (GFR) was then
calculated using the Cocroft-Gould approach [36]. Insulin resistance was calculated using fast-
ing glucose and insulin levels in the homeostasis model of insulin resistance (HOMA-IR) as
(fasting glucose (mg/dl) x fasting insulin (mU/mL))/405. CRP level was determined in serum
samples using an immunoturbidimetric assay. Serum IL-6 and IL-10 levels were determined
with the high sensitivity CBA flex kit (BD biosciences) for flow cytometry using a BD LSR-II.
Performance checks with BD CS&T tracking beads ensured constant flow cytometer perfor-
mance over the different measuring days. The samples containing the standards delivered
together with the CBA kit were measured three times. To increase accuracy, compared to the
manufacturer’s instructions an additional dilution of the standards was analysed leading to a
total of nine instead of eight controls. While IL-6 and IL-10 were determined for a subsample
of 91 participants (61% men, 69 ±4 years old), all other laboratory parameters were measured
for all 606 subjects investigated here.
Covariates
Body weight was measured in light clothes with a portable electronic scale to the nearest 0.1 kg
and height was determined to the nearest 0.1 cm by using an electronic weighing and measur-
ing station (seca 764, seca, Hamburg, Germany). The prevalence of type II diabetes mellitus
(T2D) was determined in a first step by a survey of patient’s medical history. An oral glucose
tolerance test (oGTT, 2h) was performed in case of a negative T2D history. The diagnosis of
T2D was then made based on the guidelines of the European Society of Cardiology (fasting
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glucose> 126 mg/dl, glucose after oGTT> 200 mg/dl or HbA1c> 6.5%) [37]. Assessment of
medical history also included questions on smoking status, asthma bronchiale and medication.
Regular alcohol intake was assessed by questionnaire (regular alcohol intake “yes” or “no”).
Participants were asked if they perform regularly physical activities (“yes” or “no”).
Statistical Analysis
The statistical analysis was carried out using the software package SPSS 21 for Windows (IBM
Inc., Chicago, USA). Lp(a) was divided into quintiles for further calculations. We used the Kol-
mogorov-Smirnov test to examine normal distribution of all included variables. Normally dis-
tributed variables were analyzed using the parametric Students’s t-test, variables with a skewed
distribution were analyzed with Spearman correlation and the non-parametric Mann-Whit-
ney-U-Test. Groups were compared by Chi2-test or Fisher’s exact test. Finally, multivariate
models–with FEV1, FVC and FEV1/FVC as dependent variables–were calculated to assess the
influence of low Lp(a) levels [Lp(a) quintile 1] on dependent variables, next to potential co-var-
iables. Model 3 was recalculated including hypo-/hyperthyreoidism states (subjects with TSH-
levels<0.27 mU/l were defined as hyperthyreotic and subjects with TSH-levels> 4.6 mU/l as
hypothyreotic) (model 4) and including T2D (model 5) and hormone replacement therapy
(model 6).
Results
Cross-sectional data were available for 606 subjects (55.1% females, 68 [60–84] years old). The
clinical characteristics of the participants are summarized in Table 1. Men were more fre-
quently current or former smokers. Type 2 diabetes prevalence, inflammation markers, physi-
cal activities and alcohol intake did not differ significantly between men and women. GFR used
as a measure of renal function, was significantly better in men (P<0.001). Lp(a) levels were sig-
nificantly higher in women, however, following exclusion of subjects with GFR< 60 ml/min
(n = 529; 51% women 68 (60–82) vears old) the sex difference was no longer significant (data
not shown). 9,6% of the women reported current hormone replacement therapy (n = 32).
Mean values for FEV1 and FVC were 2985±592ml and 4090±681ml in men, 2134±441ml
and 2861±513ml in women.
We found a positive correlation between FEV1 and LDL-cholesterol in women. This corre-
lation was stable even after further adjustment for age, BMI and smoking habits. The FEV1/
FVC ratio showed positive correlations with LDL-cholesterol levels and total cholesterol inde-
pendent of adjustment for age, BMI and smoking status (Table 2). FVC but not FEV1 or
FEV1/FVC-ratio was significantly (p = 0.035, data not shown) reduced in men but not women
with low cholesterol levels (< 160 mg/dl). FEV1 and FVC were clearly associated with CRP in
both sexes, whereas the other pro-inflammatory marker, IL-6, which has been analysed in a
subgroup of 91 study subjects, showed stronger correlations with FEV1 and FEV1/FVC only in
men. No significant correlations were observed between measurements of pulmonary function
and the anti-inflammatory marker IL-10 (Table 2).
Table 3 shows distributions of FEV1, FVC and FEV1/FVC according to Lp(a) quintiles. In
men, FEV1 was significantly lower (t-test) in subjects within the Lp(a) quintile 1 compared to
quintile 2–5 (Fig 1A). While this distribution was similar in women, the FEV1 difference in the
two groups did not reach statistical significance (P = 0.231). FVC did not show statistically sig-
nificant differences (t-test) in the two groups compared, i.e. Lp(a) quintile 1 vs. Lp(a) quintiles
2–5 (Fig 1B).
Other lipid parameters, inflammation markers, smoking status, alcohol intake and lipid
lowering medication did not differ significantly within the Lp(a) quintiles. However, T2D
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Table 1. Characteristics of the BASE-II participants included in the present study.
Men (n = 270) Women (n = 336) p-value
Age [years] 68 (60–80) 68 (61–84) 0.385
BMI [kg/m2] 27.1±3.5 26.5±4.8 0.077
FEV1 [ml] 2985±592 2134±441 < 0.001
FVC [ml] 4090±681 2861±513 < 0.001
FEV1/FVC [%] 74.3 (69.5–78.1) 75.4 (71.0–78.9) 0.040
Smoking status [n;%]
Current 33 (12) 35 (11)
Former 146 (54) 107 (32) < 0.001
Never 93 (34) 192 (58)
Regular alcohol intake [n;%] 245 (90) 295 (88) 0.515
Lp(a) [mg/l] 100 (40–343) 143 (70–440) 0.012
Total cholesterol [mg/dl] 203±36 227±37 < 0.001
HDL-cholesterol [mg/dl] 56±14 71±17 < 0.001
LDL-cholesterol [mg/dl] 123±33 136±34 < 0.001
Triglycerides [mg/dl] 106 (77–143) 89 (71–119) < 0.001
Apo A1 [g/l] 1.79±0.28 1.54±0.25 < 0.001
Apo B [g/l] 1.01±0.23 1.00±0.25 0.753
HOMA-IR 2.1±1.7 2.7±3.4 < 0.001
Antihyperlipidemic treatment [n;%] 53 (20) 46 (14) 0.097
Self-reported physical inactivity [n;%] 20 (7.5) 26 (7.8) 1.000
T2D [n;%] 41 (17) 38 (12) 0.087
TSH [mU/l] 1.75 (1.24–2.43) 1.85 (1.33–2.72) 0.258
GFR [ml/min] 84.6±17.2 75.6±18.0 < 0.001
CRP [mg/dl] 1.1 (0.6–2.1) 1.2 (0.6–2.3) 0.376
IL-6 [pg/ml]# 1.4 (0.8–2.2) 1.1 (0.8–1.6) 0.442
IL-10 [pg/ml]# 0.32 (0.23–0.54) 0.32 (0.17–0.43) 0.628
Results are shown as mean ±SD,median (range) or meas (interquartile range) for variables with a skewed distribution
# IL-6 and IL-10 were determined for a sub-sample of 91 participants
doi:10.1371/journal.pone.0139040.t001
Table 2. Partial correlation analysis between parameters of lung function and parameters of lipid metabolism and inflammation.
Men Women
FEV1 FVC FEV1/FVC FEV1 FVC FEV1/FVC
Total cholesterol .061 .079 -.017 .079 .018 .130*
HDL-cholesterol .080 .075 .022 -.057 -.075 .013
LDL-cholesterol .064 .073 .000 .112* -.049 .138*
Triglycerides -.108 -.076 -.076 .001 .018 -.005
Apo A1 .036 .033 -.008 -.047 -.085 .056
Apo B .018 .039 -.039 .025 -.001 .044
HOMA-IR -.012 -0.12 .012 -.066 -.105 .038
CRP -.214* -.239* -.044 -.157* -.138* -.162*
IL-6# -.404* -.325 -.357* -.081 -.093 .051
IL-10# -.085 -.006 .190 -.004 .073 -.113
Correlation coefﬁcients for partial correlation analysis adjusting for age, BMI and smoking status are shown
* = p < 0.05
# IL-6 and IL-10 were determined for a sub-sample of 91 participants
doi:10.1371/journal.pone.0139040.t002
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occured more frequently in Lp(a) quintile 1 when compared to Lp(a) quintiles 2–5, notably in
men (p = 0.020). Physical inactivity was more frequently reported in women within Lp(a)-
Quintile 1.
To assess the association of low Lp(a) [Lp(a) quintile 1] to lung volumes (FEV1, FVC and
FEV1/FVC-ratio) we further calculated linear regression models as shown in Table 4. Model 1
was simply adjusted for age and BMI. In model 2 smoking status, alcohol intake and physical
activity, as well as HOMA-IR as a marker for insulin resistance were added. Further, CRP,
Table 3. Characteristics of the study population according to Lp(a) quintile.
Men (n = 270) p-value Women (n = 336) p-value
Lp (a)-Quintile 1 Lp (a)-Quintile 2–5 Lp (a)-Quintile 1 Lp (a)-Quintile 2–5
Age [years] 67±3 69±4 0.077 67±3 68±4 0.087
BMI [kg/m2] 27.4±3.9 27.0±3.4 0.442 27.1±4.6 26.4±4.8 0.287
FEV1 [ml] 2849±494 3021±612 0.027 2069±416 2147±445 0.231
FVC [ml] 3955±560 4125±706 0.055 2769±502 2878±514 0.134
FEV1/FVC [%] 73 (68–77) 75 (70–79) 0.091 76 (72–79) 75 (71–79) 0.536
CRP [mg/dl] 1.2 (0.5–2.3) 1.1 (0.6–2.0) 0.525 1.1 (0.6–2.2) 1.2 (0.7–2.2) 0.539
IL-6 [pg/ml] # 1.0 (0.6–2–2) 1.4 (0.9–2.2) 0.483 0.92 (0.62–0.92 1.3 (0.8–1.7) 0.142
IL-10 [pg/ml] # 0.30 (0.27–0.49) 0.32 (0.22–0.57) 0.825 0.08 (0.06–0.33) 0.32 (0.22–0.43) 0.166
HOMA-IR 2.0±1.4 2.6±2.8 0.345 2.7±3.7 2.9±2.2 0.220
TSH [mU/l] 1.7 (1.2–2.4) 1.8 (1.3–2.4) 0.745 1.7 (1.2–2.4) 1.9 (1.4–2.8) 0.114
GFR [ml/min] 89.2±15.7 83.4±17.4 0.026 79.5±19.1 74.8±17.7 0.108
Self-reported physical inactivity [n;%] 3 (5) 17 (8) 0.581 8 (15) 18 (6) 0.046
T2D [n;%] 15 (30) 26 (14) 0.020 10 (21) 28 (11) 0.052
Results are shown as mean ±SD or median (interquartile range) for variables with a skewed distribution
# IL-6 and IL-10 were determined for a sub-sample of 91 participants
doi:10.1371/journal.pone.0139040.t003
Fig 1. Association of pulmonary function and Lp(a) in the Berlin Aging Study II.Measurements of (A) forced expiratory volume in 1 second (FEV1) and
(B) forced vital capacity (FVC) are shown separately for men and women to allow the comparison of pulmonary function from participants belonging to Lp(a)
quintiles 1 with pulmonary function from participants belonging to Lp(a) quintiles 2–5. Median FEV1 and FVC (black lines) was higher in subjects from Lp(a)
quintiles 2–5 in men and women. This difference was statistically significant for FEV1 in men (t-test).
doi:10.1371/journal.pone.0139040.g001
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renal function (GFR) and thyroid function (TSH) were included (model 3). Both men and
women in Lp(a) quintile 1 showed significantly reduced FEV1 and FVC in adjusted model 3.
FEV1 was reduced in men within the Lp(a)-quintile 1 compared to quintiles 2–5 by 228.6ml
and by 132.3ml in women, FVC by 238.9ml in men and by 150.8ml in women, respectively.
Distribution of FEV1/FVC, however, did not depend on Lp(a) quintiles. In addition to Lp(a)
quintile 1, age and CRP levels were associated with FEV1 and FVC, independent of sex. IL-6
and IL-10 have not been included in the calculated models because these parameters were only
available for a subgroup of 91 subjects (61% men, 69 ±4 years old).
Further adjustment for hypo- and hyperthyreoidism (model 4), T2D (model 5) and hor-
mone replacement therapy (model 6) only had a marginal impact on the Lp(a) association with
lung function. As expected, BMI and smoking habits had a statistically relevant impact on
FEV1 and FVC. Other parameters included in these models did not show a clinical or statisti-
cally relevant influence on lung function parameters (data not shown).
Recalculation of models 1 to 3 using logarithmic Lp(a) values and FEV1, FVC and FEV1/
FVC as dichotomous variables (sex specific tercentiles, see S1 File) further supported our find-
ing of the association between higher logarithmic Lp(a) levels and better lung function
(Table A in S1 File).
Discussion
In the present study, we investigated pulmonary function in the BASE-II sub-cohort of com-
munity-dwelling older participants with respect to plasma lipid profiles. Lp(a) values were sig-
nificantly higher in women, which is in accordance with the fact that Lp(a) levels increase after
menopause. Another known factor influencing the Lp(a) serum concentration is the glomeru-
lar filtration rate (GFR), which is lower in BASE-II women and thereby might additionally
explain the observed Lp(a) sex difference, as indicated by our analysis excluding subjects with
GFR< 60 ml/min [38]. Partial correlation analysis adjusting for age, BMI and smoking status
revealed positive associations of total cholesterol with FEV1/FVC, LDL-cholesterol with FEV1
and LDL-cholesterol with FEV1/FVC which were only seen in women. No correlations were
observed with respect to the apolipoproteins, Apo A1 and Apo B, and triglycerides.
Table 4. Multivariate models to assess the influence of low Lp(a) levels [Lp(a) quintile 1] on lung volumes.
Men Women
Lp(a) quintile 1 FEV1 FVC FEV1/FVC FEV1 FVC FEV1/FVC
Beta SE p Beta SE p Beta SE p Beta SE p Beta SE p Beta SE p
Model 1 -207.8 86.2 .017 -210.0 94.5 .027 -1.4 1.3 .292 -105.0 62.1 .092 -131.6 71.9 .068 0.02 1.3 .987
Model 2 -227.6 87.3 .010 -218.5 96.7 .025 -1.7 1.4 .208 -110.1 63.3 .083 -130.0 73.8 .079 -0.4 1.3 .780
Model 3 -228.6 87.9 .010 -238.9 95.2 .013 -1.4 1.4 .314 -132.3 62.7 .036 -150.8 73.4 .041 -0.5 1.3 .707
Model 4 -227.3 88.1 .011 -237.1 95.4 .014 -1.4 1.4 .321 -132.8 62.8 .035 -151.9 73.2 .039 -0.5 1.3 .703
Model 5 -217.7 89.6 .016 -212.8 96.6 .029 -1.6 1.4 .258 -127.4 62.9 .044 -142.6 73.4 .053 -0.6 1.3 .676
Model 6 -213.7 89.8 .018 -239.0 96.2 .035 -1,7 1,4 .241 -124.3 62.1 .046 -135.2 72.5 .063 -0.6 1.3 .645
Model 1: adjusted for age and BMI
Model 2: Model 1 + alcohol intake, physical activity, smoking habits, HOMA-IR
Model 3: Model 2 + CRP, TSH and GFR
Model 4: Model 3 + Hyper/Hypothyreodism
Model 5: Model 3 + T2D
Model 6: Model 5 + Hyper/Hypothyreodism + hormone replacement therapy (women)
doi:10.1371/journal.pone.0139040.t004
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The main finding of the current study is the positive association of measures of pulmonary
function, FEV1 and FVC, with Lp(a) in BASE-II participants. This result became apparent for
men in group comparisons and was seen in both sexes after adjusting for other variables poten-
tially affecting lung function and/or Lp(a) serum concentration in the regression models (mod-
els 1–4). Among the factors considered in model 3 are TSH and GFR, to control, at least in
part, for thyroid and renal function, which have been shown to modulate the Lp(a) level [38],
whereas the age of the participants, their physical activity and alcohol intake were considered
because of their known impact on pulmonary function. Inclusion of hypo- and hyperthyroid-
ism as a covariate (model 4) did not change these results significantly. Diabetes is another pos-
sible confounding factor as Lp(a) levels have been shown to be lower in diabetic patients [38].
This was also true for the participants of BASE-II studied here. A diabetic state is known to be
associated with reduced lung function [39]. Including T2D in our analysis (model 5), however,
only had a marginal impact on the association of Lp(a) and lung function in men. In women
the FVC-Lp(a) association was no longer seen after adjustment for T2D, whereas the FEV1-Lp
(a) association did not change significantly. This does not rule out that pathophysiological fac-
tors in the context of T2D might contribute to the Lp(a)-lung function association identified
here. Further, adjustment for hormone replacement therapy, which is known to lower Lp(a)-
levels, did not change these results. Recalculating model 1 to 3 with logarithmic Lp(a) values
and dichotomous values for FEV1, FVC and FEV1/FVC added further support for our result
of the positive association between Lp(a) and lung function.
While the relationship between Lp(a) and lung function has not been studied before in a
population-based cohort, it has been addressed in a clinical setting by two studies. One of these
compared the lipid profile of 90 COPD patients and a control group of 90 healthy subjects and
found significantly higher Lp(a) levels in the latter. Thus our data extend this earlier finding of
a Lp(a)-lung function association identified in a clinical COPD cohort to the general popula-
tion, at least to the group of older community-dwelling people analyzed here. The authors of
the study on the COPD cohort speculated that moderate liver failure in COPD patients might
impact on Lp(a) levels, since the liver is the exclusive site of Lp(a) synthesis [40]. This, however,
cannot explain the association of Lp(a) with lung function in our generally healthy cohort. The
other study compared only 20 COPD cases with 20 controls and found no difference in Lp(a)
concentrations between the two groups [41]. Considering the extremely skewed distribution of
Lp(a), the latter study investigating only 20 individuals in each group is certainly underpow-
ered and thereby not suited to detect reliable differences.
CRP and IL-6 were included in our partial correlation analysis as markers of general inflam-
mation processes and showed strong inverse correlations with parameters of pulmonary func-
tion in men and women. Including CRP in model 3 indicated, however, that it only has a
marginal effect on the Lp(a)-lung parameter associations. Chronic inflammation is a major fea-
ture of COPD and the association between functional lung parameters and serum markers of
chronic inflammation is well established in this clinical context [21]. Similar to our results, the
few available population-based cohort studies which investigated the relationship between
CRP and lung function also observed higher CRP to be associated with reduced functional pul-
monary parameters [17,23,42–44]. Longitudinal data from Shaban and colleagues suggest that
CRP might be predictive for declining lung function [42]. Two other longitudinal studies on
this issue yielded discrepant results [44,45]. While lung function parameters were highly corre-
lated with the proinflammatory status as determined by CRP and IL-6 in our study, we found
no difference between the CRP and IL-6 mean levels when comparing subjects with lower vs.
higher Lp(a) serum concentrations. These results suggest that increased inflammatory parame-
ters cannot explain reduced Lp(a) levels and are in line with earlier observations on another
Caucasian cohort [46].
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Although there is no obvious explanation for the relationship of Lp(a) and lung function as
observed in the current study, it may be hypothesized that Lp(a) has a so far unknown role in
lung function which is negatively affected by lower Lp(a) levels. Whether an unidentified com-
mon cause may underlie the Lp(a)-lung function association found here remains unclear.
Additionally, a role of insulin resistance and diabetes has not been ruled out completely by our
analysis and should be investigated in an independent and larger cohort. The initial idea, how-
ever, that higher levels of Lp(a) might be responsible for the increased risk of developing CVDs
in subjects with reduced lung function is not supported by our results. There is a need for addi-
tional studies with longitudinal approaches to confirm these results and to provide insight into
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